Rodriguez-Viciana Pablo, Oses-Prieto Juan, Burlingame Alma, Fried Mike, McCormick Frank
Cancer Research Institute and Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California 94143, USA.
Mol Cell. 2006 Apr 21;22(2):217-30. doi: 10.1016/j.molcel.2006.03.027.
Ras family GTPases (RFGs) are known to share many regulatory and effector proteins. How signaling and biological specificity is achieved is poorly understood. Using a proteomics approach, we have identified a complex comprised of Shoc2/Sur-8 and the catalytic subunit of protein phosphatase 1 (PP1c) as a highly specific M-Ras effector. M-Ras targets Shoc2-PP1c to stimulate Raf activity by dephosphorylating the S259 inhibitory site of Raf proteins bound to other molecules of M-Ras or Ras. Therefore, distinct RFGs, through independent effectors, can regulate different steps in the activation of Raf kinases. Shoc2 function is essential for activation of the MAPK pathway by growth factors. Furthermore, in tumor cells with Ras gene mutations, inhibition of Shoc2 expression inhibits MAPK, but not PI3K activity. We propose that the Shoc2-PP1c holoenzyme provides an attractive therapeutic target for inhibition of the MAPK pathway in cancer.
已知Ras家族GTP酶(RFGs)共享许多调节蛋白和效应蛋白。目前对如何实现信号传导和生物学特异性了解甚少。我们采用蛋白质组学方法,鉴定出一个由Shoc2/Sur-8和蛋白磷酸酶1催化亚基(PP1c)组成的复合物,它是一种高度特异性的M-Ras效应器。M-Ras靶向Shoc2-PP1c,通过使与其他M-Ras或Ras分子结合的Raf蛋白的S259抑制位点去磷酸化来刺激Raf活性。因此,不同的RFGs可通过独立的效应器调节Raf激酶激活的不同步骤。Shoc2的功能对于生长因子激活MAPK途径至关重要。此外,在具有Ras基因突变的肿瘤细胞中,抑制Shoc2表达可抑制MAPK,但不抑制PI3K活性。我们认为,Shoc2-PP1c全酶为癌症中MAPK途径的抑制提供了一个有吸引力的治疗靶点。